American Journal of Epidemiology Vol. 137, No. 11: 1229-1240
Copyright © 1993 by The Johns Hopkins University School of Hygiene and Public Health
research-article |
Effect of Routine Use of Therapy in Slow ing the Clinical Course of Human Immunodeficiency Virus (HIV) Infection in a Population-based Cohort
1Division of Biostatistics, Emory University School of Public Health Atlanta, GA
2Division of HIV/.AIDS, Centers for Disease Control and Prevention Atlanta, GA
Reprint requests to Di Ira M. Longini, Jr., Division of Biostatistics, Emory University School of Public Health, Atlanta, GA 30322.
Clinical trials have shown that the prophylactic use of zidovudine and aerosolized pentamidine (or other antibiotics used as prophylaxis against Pneumocystis carinii pneumonia) in acquired immunodeficiency syndrome (AIDS)-free human immunodeficiency virus (HIV)-infected persons delays the development of AIDS, but the effectiveness of such therapy in general use in the population still remains largely undocumented. To help answer this question, the authors estimate the effectiveness of this therapy in a population-based cohort of HIV-infected homosexual and bisexual men in San Francisco. The authors use a continuous-time Markov process to model the decline of CD4+ T-lymphocytes (T4-cells) measured in cells/µliter in HIV-infected persons. The model partitions the HIV (type 1) infection period into six progressive T4-cell count intervals (stages), followed by a seventh stage: AIDS diagnosis. The authors use maximum likelihood methods to fit the model to the observed transitions for 428 HIV infected men during June 1984 to March 1991, from the San Francisco Men's Health Study. Since zidovudine was not widely used before 1988, the model has a component that controls for calendar time-related biases. The fitted model provides statistical estimates and confidence intervals for measuring therapy effectiveness. The authors estimate that prophylactic therapy reduces the progression rate from stage 4 (T4-cell count, 350–499) to stage 5 (T4-cell count, 200–349) by a factor of 0.26(95% confidence interval (CI) –0.22 to 0.55); from stage 5 to stage 6 (T4-cell count <200) by a factor of 0.33 (95% Cl 0.04–0.54); and from stage 6 to 7 (AIDS) by a factor of 0.62 (95% CI 0.47–0.73). In addition, therapy started by an HIV-infected person in stage 4 is estimated to reduce the risk of developing AIDS by a factor of 0.83 (95% CI 0.46–0.94) at 6 months and 0.68 (95% CI 0.35–0.89) at 24 months after entering stage 4. Therapy started by HIV-infected persons in more advanced stages is estimated to reduce the risk of developing AIDS by factors ranging from 0.70 (95% CI 0.39-0.90), early in stage 5, to 0.28(95% CI 0.14–0.45), late in stage 6. Thus, the prophylactic use of zidovudine and pentamidine in routine medical care has a strong, consistent, and significant effect in slowing the clinical course of HIV infection in a population-based cohort.
acquired immunodeficiency syndrome; HIV-1; T4 lymphocytes; Markov process; maximum likelihood estimates; pentamidine; zidovudine
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. M. Tarwater, J. Mellors, M. E. Gore, J. B. Margolick, J. Phair, R. Detels, and A. Munoz Methods to Assess Population Effectiveness of Therapies in Human Immunodeficiency Virus Incident and Prevalent Cohorts Am. J. Epidemiol., October 1, 2001; 154(7): 675 - 681. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Ahdieh, S. J. Gange, R. Greenblatt, H. Minkoff, K. Anastos, M. Young, M. Nowicki, A. Kovacs, M. Cohen, and A. Munoz Selection by Indication of Potent Antiretroviral Therapy Use in a Large Cohort of Women Infected with Human Immunodeficiency Virus Am. J. Epidemiol., November 15, 2000; 152(10): 923 - 933. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Hendriks, K. J. Craib, P. J Veugelers, H. A. van Druten, R. A Coutinho, M. T Schechter, and G. J. van Griensven Secular trends in the survival of HIV-infected homosexual men in Amsterdam and Vancouver estimated from a death-included CD4-staged Markov model Int. J. Epidemiol., June 1, 2000; 29(3): 565 - 572. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Scharfstein, A. D. Paltiel, and K. A. Freedberg The Cost-Effectiveness of Fluconazole Prophylaxis against Primary Systemic Fungal Infections in AIDS Patients Med Decis Making, October 1, 1997; 17(4): 373 - 381. [Abstract] [PDF]
|
|
|
|
 |
|
 N. M.H. Graham, D. R. Hoover, L. P. Park, D. S. Stein, J. P. Phair, Mellors John W. MD, R. Detels, and A. J. Saah Survival in HIV-Infected Patients Who Have Received Zidovudine: Comparison of Combination Therapy with Sequential Monotherapy and Continued Zidovudine Monotherapy Ann Intern Med, June 15, 1996; 124(12): 1031 - 1038. [Abstract] [Full Text]
|
|
|
|
|
|
D. S. Stein, N. M. H. Graham, L. P. Park, D. R. Hoover, J. P. Phair, R. Detels, M. Ho, and A. J. Saah The Effect of the Interaction of Acyclovir with Zidovudine on Progression to AIDS and Survival: Analysis of Data in the Multicenter AIDS Cohort Study Ann Intern Med, July 15, 1994; 121(2): 100 - 108. [Abstract] [Full Text]
|
|